股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 FF301 公司名稱: 叮噹健康科技集團有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | 本月底法 ...

据悉，蚂蚁阿福与叮当健康围绕"智慧药房+即时履约"等方面展开合作。叮当健康通过天眼智址、AI库 存管理与实时调度系统，确保当用户被引导至叮当智慧药房时，能够即时响应并高效履约，这正是AI 健康服务得以落地、赢得用户信任的运营基石。 凭借覆盖全国多城市的"28分钟送药到家"叮当智慧药房网络、支持医保支付的叮当智慧药房以及24小时 在线的药师服务，叮当健康高效承接了"医疗AI服务落地"这一关键环节，使AI健康管理从"建议"走 向"解决"，形成了"AI指导+即时专业服务"的完整用户体验闭环。 近日，蚂蚁阿福升级其PC端，并上线DeepSearch(深度搜索)功能打造中国版"Open Evidence"，免费为医 生、医学生及基层医疗工作者等泛医学人士提供专业服务。此次PC端的升级，标志着蚂蚁阿福在用户 端+医生端的双端布局进一步成熟。 在用户端，蚂蚁阿福单日用户提问量已超1000万。依托自研的蚂蚁医疗健康大模型，蚂蚁阿福为全国医 生开放"AI分身"技术，超1000位医生在阿福App上开设了自己的AI分身，7*24小时在线回答用户的健康 咨询。 ...

Group 1 - The core point of the article is that Dingdang Health has been actively repurchasing its shares, with a total of 2,398.85 million shares repurchased since November 25, 2025, amounting to 2,666.24 million HKD [2] - On January 16, 2026, the company repurchased 5.2145 million shares at a price range of 1.050 to 1.240 HKD, with a total repurchase amount of 584.22 million HKD [2] - The stock price closed at 1.090 HKD on the same day, reflecting a decline of 11.38%, with a total trading volume of 17.4298 million HKD [2] Group 2 - Year-to-date, the company has conducted 11 repurchase transactions, totaling 1,473.20 million shares and a total repurchase amount of 1,672.21 million HKD [2] - The stock has experienced a cumulative increase of 5.83% during the repurchase period [2] - A detailed breakdown of the repurchase activities shows varying amounts and prices, with the highest repurchase price recorded at 1.240 HKD on January 16, 2026 [2]

Group 1 - The core point of the article is that Dingdang Health has been actively repurchasing its shares, with a total of 5.21 million shares bought back on January 16 at prices ranging from 1.050 to 1.240 HKD, amounting to 5.84 million HKD [1] - Since November 25, 2025, the company has conducted share repurchases for 36 consecutive days, totaling 23.99 million shares and a cumulative repurchase amount of 26.66 million HKD [1] - The stock has seen a cumulative increase of 5.83% during the repurchase period [1] Group 2 - In 2026, the company has completed 11 repurchase transactions, acquiring a total of 14.73 million shares for a total amount of 16.72 million HKD [1] - The detailed repurchase data shows varying prices and amounts, with the highest repurchase price recorded at 1.240 HKD and the lowest at 1.050 HKD on January 16 [1] - The stock closed at 1.090 HKD on the same day, reflecting an 11.38% decline with a total trading volume of 17.43 million HKD [1]

Core Viewpoint - Dingdang Health (09886) announced a share buyback plan, indicating confidence in its stock value and potential for future growth [1] Group 1: Buyback Details - The company will repurchase 5.2145 million shares at a total cost of HKD 5.8422 million [1] - The buyback price per share ranges from HKD 1.05 to HKD 1.24 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 叮噹健康科技集團有限公司 呈交日期： 2026年1月16日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09886 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔 ...

Group 1 - The company Dingdong Health (09886) announced a share buyback plan, intending to repurchase approximately 2.866 million shares at a cost of about HKD 3.4805 million [1] - The share buyback is scheduled for January 15, 2026, indicating the company's strategy to enhance shareholder value [1] - This move reflects the company's confidence in its financial position and future prospects [1]

Group 1 - The company Dingdang Health (09886.HK) announced a share buyback on January 15, spending HKD 3.481 million to repurchase 2.866 million shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 叮噹健康科技集團有限公司 FF305 | 1). | 已購回以作註銷但尚未註銷之股份 | | 410,000 | 0.031073 % | HKD | 1.051 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年11月25日 | | | | | | 2). | 已購回以作註銷但尚未註銷之股份 | | 170,000 | 0.012884 % | HKD | 1.0533 | | | 變動日期 | 2025年11月26日 | | | | | | 3). | 已購回以作註銷但尚未註銷之股份 | | 69,000 | 0.005229 % | HKD | 1.0787 | | | 變動日期 | 2025年11月27日 | | | | | | 4). | 已購回以作註銷但尚未註銷之股份 | | 251,000 | 0.019023 % | HKD | 1.0888 | | | 變動日期 | ...

Group 1 - The core viewpoint of the articles highlights Dingtang Health's strategic expansion in Shanghai, with the opening of 20 new Dingtang Smart Pharmacies to enhance service coverage in key cities [1] - Dingtang Health has established a high-density store network in major cities like Beijing, Shanghai, and Shenzhen, focusing on improving accessibility and convenience for residents [1] - The new pharmacies will offer online medical insurance payment and 24/7 home delivery services, along with a "cold chain to home" service [1] Group 2 - For the first half of 2025, Dingtang Health reported revenues of 2.327 billion yuan, a year-on-year increase of 2.6%, with a gross profit of 816 million yuan and a gross margin of 35% [2] - The company narrowed its losses to 52.02 million yuan, a 42.1% improvement compared to the same period in 2024, and adjusted net profit losses were reduced by 78.2% to 575,900 yuan [2] - Dingtang Health plans to focus on user lifecycle health management and full-course management, while enhancing its product and sales capabilities to expand its service density in major cities [2]